Clinical and immunopathological evaluation of epidermolysis bullosa acquisita
Carregando...
Citações na Scopus
35
Tipo de produção
article
Data de publicação
2011
Título da Revista
ISSN da Revista
Título do Volume
Editora
WILEY-BLACKWELL PUBLISHING, INC
Autores
Citação
CLINICAL AND EXPERIMENTAL DERMATOLOGY, v.36, n.1, p.12-18, 2011
Resumo
P>Background. Epidermolysis bullosa acquisita (EBA) is a subepidermal blistering disease with IgG antibodies against collagen VII. The disease is heterogeneous and can lead to significant morbidity. Aim. To characterize the clinical and laboratory profile of patients with EBA from Sao Paulo, Brazil. Methods. In total, 12 patients (mean age 24 years) were analysed for cutaneous and mucosal involvement, laboratory data and response to treatment. Results. Mucosal involvement occurred in 11 of the 12 patients (eyes in 4/12, nose in 4/9, pharynx-larynx in 5/9 and oesophagus in 4/10; 3 patients did not undergo nasopharyngeal examination and 2 paediatric patients did not undergo endoscopy). Using direct immunofluorescence, different patterns of deposits were found at the basement membrane zone: IgG (12/12), IgA (6/12), IgM (4/12), C3 (11/12). Indirect immunofluorescence (IIF) was positive in 6 of 12 patients, and IIF on salt-split skin detected dermal deposition in 10 of 12 patients. Antinuclear antibodies were found in 3 of 12 patients, but none of them fulfilled the criteria for systemic lupus erythematosus. After treatment, total remission was achieved in three patients and partial remission in five (three were maintained on minimal treatment, one on the full treatment and one was able to come off treatment). Two patients were lost to follow-up and the remaining two had disease flares. Complications were mainly mucosal (oesophageal stenosis, laryngeal synechia, symblephara and trichiasis). Conclusions. Mucosal involvement in EBA is a determining factor for disease morbidity. Complete evaluation of the patient, focusing on both cutaneous and extracutaneous sites is essential, as EBA may evolve to refractory disease, severely compromising its outcome.
Palavras-chave
Referências
- Murrell DE, 2008, J AM ACAD DERMATOL, V58, P1043, DOI 10.1016/j.jaad.2008.01.012
- CallotMellot C, 1997, ARCH DERMATOL, V133, P1122, DOI 10.1001/archderm.133.9.1122
- Mayuzumi M, 2006, BRIT J DERMATOL, V155, P1048, DOI 10.1111/j.1365-2133.2006.07443.x
- Suchniak JM, 2002, ARCH DERMATOL, V138, P1385, DOI 10.1001/archderm.138.10.1385
- Chen M, 2007, AM J PATHOL, V170, P2009, DOI 10.2353/ajpath.2007.061212
- Vodegel RM, 2002, J AM ACAD DERMATOL, V47, P919, DOI 10.1067/mjd.2002.125079
- Caux F, 1997, BRIT J DERMATOL, V137, P270, DOI 10.1046/j.1365-2133.1997.18191915.x
- Chan LS, 1999, ARCH DERMATOL, V135, P569, DOI 10.1001/archderm.135.5.569
- WOODLEY DT, 1988, J CLIN INVEST, V81, P683, DOI 10.1172/JCI113373
- Mihai S, 2007, J CELL MOL MED, V11, P462, DOI 10.1111/j.1582-4934.2007.00033.x
- Diaz LA, 2000, ARCH DERMATOL, V136, P106, DOI 10.1001/archderm.136.1.106
- ELLIOT FI, 1895, J CUTAN GENITOURIN D, V13, P10
- Hallel-Halevy D, 2001, CLIN DERMATOL, V19, P712, DOI 10.1016/S0738-081X(00)00186-3
- KIRTSCHIG G, 2009, COCHRANE LIB, V1
- MARKHAM CL, 1999, ARCH DERMATOL, V139, P954
- PRUSSICK R, 1994, INT J DERMATOL, V33, P192
- Trigo-Guzman FX, 2003, J DERMATOL, V30, P226
- Vassileva S, 2004, CLIN DERMATOL, V22, P129, DOI 10.1016/j.clindermatol.2003.12.020
- WOODLEY DT, 1984, NEW ENGL J MED, V310, P1007, DOI 10.1056/NEJM198404193101602